Sunshine Act Meetings, 63674 [2018-26925]
Download as PDF
63674
Federal Register / Vol. 83, No. 237 / Tuesday, December 11, 2018 / Notices
handbook_on_electronic_filing.pdf).
Persons with questions regarding filing
should contact the Secretary (202–205–
2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel, solely for cybersecurity
purposes (all contract personnel will
sign appropriate nondisclosure
agreements). All nonconfidential
written submissions will be available for
public inspection at the Office of the
Secretary and on EDIS.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: December 4, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–26740 Filed 12–10–18; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–18–058]
amozie on DSK3GDR082PROD with NOTICES1
Sunshine Act Meetings
December 14, 2018 at
11:00 a.m.
PLACE: Room 101, 500 E Street SW,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
TIME AND DATE:
VerDate Sep<11>2014
17:51 Dec 10, 2018
Jkt 247001
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote on Inv. Nos. 701–TA–598 and
731–TA–1408 (Final)(Rubber Bands
from China). The Commission is
currently scheduled to complete and file
its determinations and views of the
Commission by December 27, 2018.
5. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: December 7, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–26925 Filed 12–7–18; 4:15 pm]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Antitrust Division
United States et al. v. The CharlotteMecklenburg Hospital Authority, d/b/a
Carolinas Healthcare System;
Proposed Final Judgment and
Competitive Impact Statement
Notice is hereby given pursuant to the
Antitrust Procedures and Penalties Act,
15 U.S.C. § 16(b)–(h), that a proposed
Final Judgment, Stipulation, and
Competitive Impact Statement have
been filed with the United States
District Court for the Western District of
North Carolina in United States and
State of North Carolina. v. The
Charlotte-Mecklenburg Hospital
Authority, d/b/a Carolinas HealthCare
System, Civil Action No. 3:16–cv–
00311–RJC–DCK. On June 6, 2016, the
United States and the State of North
Carolina filed a Complaint alleging that
The Charlotte-Mecklenburg Hospital
Authority formerly known as Carolinas
HealthCare System (or CHS) and now
doing business as Atrium Health
(‘‘Atrium’’) included provisions in its
contracts with health insurers that
restricted insurers from steering their
members to lower-cost, high-quality
providers, in violation of Section 1 of
the Sherman Act, 15 U.S.C. § 1. The
proposed Final Judgment, filed
November 15, 2018, enjoins Atrium
from (1) enforcing provisions in its
current insurer contracts that restrict
steering and transparency; (2) having
contract provisions with an insurer that
would prohibit, prevent or significantly
restrain the insurer from using certain
steering methods or providing
transparency; and (3) penalizing, or
threatening to penalize, any insurer for
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
its use of certain steering methods and
transparency.
Copies of the Complaint, proposed
Final Judgment, and Competitive Impact
Statement are available for inspection
on the Antitrust Division’s website at
https://www.justice.gov/atr and at the
Office of the Clerk of the United States
District Court for the Western District of
North Carolina. Copies of these
materials may be obtained from the
Antitrust Division upon request and
payment of the copying fee set by
Department of Justice regulations.
Public comment is invited within 60
days of the date of this notice. Such
comments, including the name of the
submitter, and responses thereto, will be
posted on the Antitrust Division’s
website, filed with the Court, and, under
certain circumstances, published in the
Federal Register. Comments should be
directed to Peter J. Mucchetti, Chief,
Healthcare and Consumer Products
Section, Antitrust Division, Department
of Justice, 450 Fifth Street NW, Suite
4100, Washington, DC 20530
(telephone: 202–307–0001).
Patricia A. Brink,
Director of Civil Enforcement.
United States District Court for the Western
District of North Carolina Charlotte Division
United States of America and the State of
North Carolina, Plaintiffs, v. The CharlotteMecklenburg Hospital Authority, d/b/a
Carolinas Healthcare System, Defendant.
Case No. 3:16–cv–00311–RJC–DCK
Judge Robert J. Conrad, Jr.
COMPLAINT
The United States of America and the State
of North Carolina bring this civil antitrust
action to enjoin Defendant, The CharlotteMecklenburg Hospital Authority, d/b/a
Carolinas HealthCare System (‘‘CHS’’), from
using unlawful contract restrictions that
prohibit commercial health insurers in the
Charlotte area from offering patients financial
benefits to use less-expensive healthcare
services offered by CHS’s competitors. These
steering restrictions reduce competition
resulting in harm to Charlotte area
consumers, employers, and insurers.
I. CHS AND ITS UNLAWFUL STEERING
RESTRICTIONS
1. CHS is a North Carolina not-for-profit
corporation providing healthcare services
with its principal place of business in
Charlotte. Its flagship facility is Carolinas
Medical Center, a large general acute-care
hospital located in downtown Charlotte. It
also operates nine other general acute-care
hospitals in the Charlotte area.
2. CHS is the dominant hospital system in
the Charlotte area, with approximately a 50
percent share of the relevant market, and
2014 revenue of approximately $8.7 billion.
Its closest competitor by size is Novant,
which owns five general acute care hospitals
in the Charlotte area and has less than half
E:\FR\FM\11DEN1.SGM
11DEN1
Agencies
[Federal Register Volume 83, Number 237 (Tuesday, December 11, 2018)]
[Notices]
[Page 63674]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-26925]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[USITC SE-18-058]
Sunshine Act Meetings
TIME AND DATE: December 14, 2018 at 11:00 a.m.
PLACE: Room 101, 500 E Street SW, Washington, DC 20436, Telephone:
(202) 205-2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote on Inv. Nos. 701-TA-598 and 731-TA-1408 (Final)(Rubber
Bands from China). The Commission is currently scheduled to complete
and file its determinations and views of the Commission by December 27,
2018.
5. Outstanding action jackets: None.
In accordance with Commission policy, subject matter listed above,
not disposed of at the scheduled meeting, may be carried over to the
agenda of the following meeting.
By order of the Commission.
Issued: December 7, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018-26925 Filed 12-7-18; 4:15 pm]
BILLING CODE 7020-02-P